ClinicalTrials.gg
RecruitingNCT06758921Updated Jan 6, 2025

Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Peripheral Multifunctional Catheter for the Dilatation of Lesions in the Femoral, Popliteal and Infrapopliteal Arteries (BIO-OSCAR First)

An observational study in Peripheral Arterial Disease and Peripheral Arterial Disease(PAD), sponsored by Biotronik AG. Recruiting at 16 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG — 1 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Biotronik SE & Co. KG.

Started
2024
with 1 other
Observational
7 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 15th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

1 of the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG is open now, in 8 countries.

By country, each count listing its studies:

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.

Read the detailed description

This is a prospective, multicenter, all-comers observational study. Primary endpoint was procedural success (defined as a combination of successful primary target lesion crossing, residual stenosis of ≤30% following vessel preparation and before definite treatment) and absence of procedural complications (defined as target vessel perforation or rupture, acute occlusion, and distal embolization).

03

Conditions studied

  • Peripheral Arterial Disease
  • Peripheral Arterial Disease(PAD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A total of 200 patients will be enrolled, with approximately 100 subjects in ATK group, and 100 subjects in BTK group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject ≥18 years old
  2. Subject has provided written
  3. Subject has Rutherford classification 2 to 6
  4. Reference vessel diameter ≥2 and ≤7 mm
  5. Target lesion(s) has stenosis >70% by visual assessment
  6. Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.

    Above the knee (ATK) group:

  7. Target lesions located in the superficial femoral artery or popliteal arteries (above the tibial plateau)
  8. At least one below-knee artery patent to the ankle
  9. Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.

    Below the knee (BTK) group:

  10. Target lesions involve arteries below the tibial plateau
  11. Successful treatment of inflow vessel (from ipsilateral iliac to the target lesion) resulting in ≤30% residual stenosis with no evidence of embolization or significant complications

Exclusion criteria

Exclusion Criteria:

  1. Subject has a single target lesion that involves both ATK and BTK segments.
  2. Subject not suitable for receiving endovascular procedures of lower limb arteries.
  3. Prior planned major amputation in the target limb (i.e., above the ankle).
  4. Subject with previous bypass surgery of target vessel.
  5. History of any open surgical procedure within the past 30 days.
  6. Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb.

    Note: The inflow vessels can be treated on the day of the procedure.

  7. Subject has Oscar IFU listed (such as uncorrected bleeding disorders, sepsis).
  8. Subject under dialysis.
  9. Subject currently enrolled in another device, biologic, or drug trial in which the primary endpoint has not yet been reached.
  10. Subject lacking capacity to provide .
  11. Subject under judicial protection, tutorship, or curatorship (for France only).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Interventions

  • DeviceOscar Peripheral Multifunctional Catheter

    Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon. Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU).

06

What researchers measure

Primary outcomes

  1. Oscar Procedural success rate

    combination of Oscar technical success and absence of serious procedural complications

    Time frame: Index procedure

Secondary outcomes

  1. Rate of (Serious) Adverse Device Effects (S)ADE

    (Serious) Adverse Device Effects

    Time frame: discharge (30 days)

  2. Rate of distal embolization

    Distal embolization

    Time frame: Index procedure

  3. Rate of target vessel rupture

    Target vessel rupture

    Time frame: Index procedure

  4. Rate of target vessel perforation

    Target vessel perforation

    Time frame: Index procedure

  5. Rate of target vessel acute occlusion

    Target vessel acute occlusion

    Time frame: Index procedure

  6. Rate of Oscar PTA balloon related flow-limiting dissections

    flow-limiting dissections defined as NHLBI grade ≥D

    Time frame: Index procedure

  7. Rate of peri-operative death (all-cause of death until discharge)

    peri-operative death defined as all-cause of death until discharge

    Time frame: discharge (30 days)

  8. Rate of unplanned major amputation

    unplanned major amputation

    Time frame: discharge (30 days)

  9. Oscar crossing success

    angiographic confirmation of successful placement of a guidewire into the distal true lumen with Oscar support catheter used together with the dilator and/ or Oscar PTA balloon, and without any additional crossing/re-entry device.

    Time frame: Index procedure

  10. Post-Oscar residual stenosis

    Post-Oscar residual stenosis (%)

    Time frame: Index procedure

  11. Final treatment residual stenosis (%) on the completion angiogram

    Final residual stenosis (%) on the completion angiogram

    Time frame: Index procedure

07

Study locations

2 of 16 sites recruiting
  • LKH Univ. -Klinikum Graz, Ambulanz für Angiologie
    Graz, 8036, Austria
    Recruiting
    • Marianne Brodmann, Prof. Dr. med · Principal investigator
  • Onze Lieve Vrouwziekenhuis
    Aalst, 9300, Belgium
    Not yet recruiting
    • Lieven Maene, MD · Principal investigator
  • AZ Saint Blasius
    Dendermonde, 9200, Belgium
    Recruiting
    • Koen Deloose, MD · Principal investigator
  • ZOL Ziekenhuis Oost Limburg
    Genk, 3600, Belgium
    Not yet recruiting
    • Wouter Lansink, MD · Principal investigator
  • University Hospital Ghent
    Ghent, 9000, Belgium
    Not yet recruiting
    • Bernard Peeters, MD · Principal investigator
  • vzw AZ Groeninge
    Kortrijk, 8500, Belgium
    Not yet recruiting
    • Philippe Lerut, MD · Principal investigator
  • Hopital Saint Joseph
    Paris, 75674, France
    Not yet recruiting
    • Yann Goueffic, Prof. MD · Principal investigator
  • Karolinen-Hospital Arnsberg
    Arnsberg, 59759, Germany
    Not yet recruiting
    • Michael Lichtenberg, Dr. Med · Principal investigator
  • Sankt Gertrauden-Krankenhaus
    Berlin, 10713, Germany
    Not yet recruiting
    • Ralf Langhoff, Dr. Med · Principal investigator
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
    Not yet recruiting
    • Jörg Schmehl, Dr. Med · Principal investigator
  • Semmelweis University
    Budapest, 1085, Hungary
    Not yet recruiting
    • Balazs Nemes, MD · Principal investigator
  • Policlinico Abano Terme
    Abano Terme, 35031, Italy
    Not yet recruiting
    • Marco Manzi, MD · Principal investigator
  • Azienda Usl Toscana sud est
    Arezzo, 52100, Italy
    Not yet recruiting
    • Francesco Liistro, MD · Principal investigator
  • ospedaliero-universitaria Senese
    Siena, 53100, Italy
    Not yet recruiting
    • Gianmarco de Donato, Prof. MD · Principal investigator
  • Hospital Universitario de Guadalajara
    Guadalajara, 19002, Spain
    Not yet recruiting
    • Mercedes Guerra, MD · Principal investigator
  • Ospedale Regionale civico EOC di Lugano
    Lugano, 6962, Switzerland
    Not yet recruiting
    • Maria Antonella Ruffino, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Not yet decided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 12 months is below that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Jan 6, 2025
StartActual
Dec 19, 2024
Primary completionEst.
Dec 20, 2025
CompletionEst.
Jan 20, 2026
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06758921
Lead sponsor
Biotronik AG
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Dec 19, 2024
Primary completion
Dec 20, 2025 (estimated)
Completion
Jan 20, 2026 (estimated)
Last update
Jan 6, 2025

Study contacts

Helene Kuissu, PharmD
Contact
helene.kuissu@biotronik.com
+41 44 864 54 80
Koen Deloose
principal investigator · AZ Saint Blasius

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion